Arizona State Retirement System Invests $2.01 Million in Medpace Holdings Inc (MEDP) Stock

Share on StockTwits

Arizona State Retirement System acquired a new position in Medpace Holdings Inc (NASDAQ:MEDP) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 37,900 shares of the company’s stock, valued at approximately $2,006,000. Arizona State Retirement System owned approximately 0.11% of Medpace at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc raised its stake in shares of Medpace by 63.6% during the 3rd quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock worth $173,601,000 after purchasing an additional 1,126,649 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after acquiring an additional 1,126,649 shares in the last quarter. BlackRock Inc. raised its stake in shares of Medpace by 42.1% in the 3rd quarter. BlackRock Inc. now owns 2,282,063 shares of the company’s stock valued at $136,719,000 after acquiring an additional 676,396 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Medpace by 14.2% in the 3rd quarter. Acadian Asset Management LLC now owns 1,464,121 shares of the company’s stock valued at $87,717,000 after acquiring an additional 182,588 shares in the last quarter. Finally, Laurion Capital Management LP raised its stake in shares of Medpace by 63.1% in the 3rd quarter. Laurion Capital Management LP now owns 1,108,556 shares of the company’s stock valued at $66,414,000 after acquiring an additional 428,785 shares in the last quarter. 71.88% of the stock is owned by hedge funds and other institutional investors.

MEDP has been the topic of a number of recent analyst reports. BidaskClub downgraded Medpace from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 8th. ValuEngine raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, January 10th. Zacks Investment Research raised Medpace from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Thursday, November 1st. Finally, SunTrust Banks raised Medpace from a “hold” rating to a “buy” rating and set a $63.00 price objective on the stock in a research note on Wednesday, October 31st. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Medpace has a consensus rating of “Buy” and an average target price of $44.43.

Shares of MEDP stock opened at $67.09 on Thursday. The company has a market capitalization of $2.29 billion, a P/E ratio of 44.14, a P/E/G ratio of 1.36 and a beta of 1.76. The company has a current ratio of 0.66, a quick ratio of 0.66 and a debt-to-equity ratio of 0.25. Medpace Holdings Inc has a twelve month low of $31.75 and a twelve month high of $69.71.

In other Medpace news, major shareholder Medpace Investors, Llc sold 103,013 shares of the firm’s stock in a transaction that occurred on Monday, February 4th. The stock was sold at an average price of $65.72, for a total value of $6,770,014.36. Following the sale, the insider now owns 7,770,045 shares of the company’s stock, valued at approximately $510,647,357.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 18,920 shares of the firm’s stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $66.54, for a total value of $1,258,936.80. Following the completion of the sale, the chief executive officer now directly owns 603,702 shares in the company, valued at approximately $40,170,331.08. The disclosure for this sale can be found here. Insiders sold a total of 660,817 shares of company stock worth $41,996,365 in the last ninety days. Insiders own 29.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2019/02/14/arizona-state-retirement-system-invests-2-01-million-in-medpace-holdings-inc-medp-stock.html.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Read More: What are different types of coverage ratios?

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply